PPARA and colonic neoplasm: Notably, the PPAR pan-agonist bezafibrate increased the proliferation and survival of tumor-reactive CD8+ T cells; it also enhanced the inhibition effect of colon cancer development in mice when combined with PD-1 blockade [36].